10-K annual report · filed Nov 12, 2026

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 10-K Annual Report

Short answer

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed its fiscal 2026 10-K annual report with the SEC on Nov 12, 2026. It reported revenue of $451M (−45.6% year over year) and net income of −$724M.

  • Top risk flagged: FDA approval risk: plozasiran sNDA for sHTG remains pending despite STAR pilot entry

FY2026 key financial metrics · XBRL

Revenue
$451M
−45.6% YoY
Net income
−$724M
−44302.6% YoY
Operating margin
-156.9%
−168.7 pp YoY
EPS (diluted)
−$5.11
−51000.0% YoY
ROE
-1439.4%
−1439.1 pp YoY
Operating cash flow
−$272M
−251.5% YoY

Source: XBRL data from the ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 10-K on SEC EDGAR. USD.

ARROWHEAD PHARMACEUTICALS, INC. FY2026 10-K analysis

AI summary of each section, grounded in the filing text

Business Overview

  • RNAi biopharmaceutical model: proprietary TRiM platform develops gene-silencing medicines, with partnered programs funding wholly owned assets
  • First commercial product REDEMPLO launched in 2025, with approvals expanded to the EU, Canada, Australia, China and UK
  • Strategic shift toward commercialization: commercial organization built for FCS and larger footprint planned for potential sHTG launch in Q2 2027
  • Plozasiran Phase 3 results: median triglyceride reductions of 79% and 81% at Month 12, with STAR pilot acceptance for the sNDA
  • Workforce expanded to 1,062 employees across the United States, Switzerland and New Zealand, supporting commercialization, manufacturing and R&D growth

Management Discussion & Analysis

  • Revenue $450.8M, down $378.6M YoY from $829.4M, driven by lower Sarepta and Sanofi collaboration revenue
  • Net loss $724.2M vs $1.6M; operating loss $707.2M vs operating income $98.3M
  • Best performer: Sarepta revenue $316.9M; worst: Sanofi revenue $13.3M, down from $130.0M
  • Operating cash flow $(271.9)M; capex $12.0M; PRV purchase $215.0M; convertible-note proceeds $681.3M
  • Outlook: liquidity sufficient for at least 12 months; planned U.S. sHTG launch in Q2 2027 pending approval

Risk Factors

  • FDA approval risk: plozasiran sNDA for sHTG remains pending despite STAR pilot entry
  • Pricing pressure: CMS GLOBE Medicare Part B model begins in 2027 and faces pending litigation
  • Supply-chain exposure: reliance on third parties in China creates BIOSECURE Act and tariff disruption risk
  • Competitive disruption: generic REDEMPLO versions could erode sales if exclusivity is inadequate
  • Leverage constraint: Sixth Street financing agreement could accelerate debt repayment upon covenant breach

Generated from the filing text; verify against the original. How to read a 10-K

Other ARROWHEAD PHARMACEUTICALS, INC. annual reports

Ask about this 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.